



July 21, 2008

Dear Doctor,

We are sending this letter to inform you of changes to Caterpillar's prescription drug benefit coverage of the following bisphosphonates:

- **Actonel[®] (all strengths)**
- **Boniva[®] (all strengths)**

In February 2008, **Fosamax[®]** became the first bisphosphonate to have a generic equivalent (**alendronate**). So, as part of Caterpillar's initiative to promote cost-effective drug therapy, Caterpillar's prescription drug benefit plan will institute the following changes:

Effective August 1, 2008:

- A step therapy / prior authorization (PA) program for bisphosphonates for all **NEW** users will be implemented as follows:
 - Step A: **alendronate** (Fosamax); no PA required
 - Step B: **Actonel**; covered only after a trial of Step A
 - Step C: **Boniva**; only an option for 4-tier formulary (which includes the \$0 Select Tier) through October 31. Covered after a PA and trials of both Step A and Step B for members on a 2 or 3-tier formulary.

Effective November 1, 2008:

- A step therapy / prior authorization program for bisphosphonates for all **CURRENT** users will be implemented as follows:
 - Step A: **alendronate** (Fosamax); no PA required
 - Step B: **Actonel**; covered only after a trial of Step A
- For members covered by Caterpillar's 4-tier (\$0, \$5, \$20, \$35) prescription drug formulary for certain Salaried/Management/Non-Bargained Hourly participants, **Boniva** will no longer be covered as of November 1, 2008. Members on the four-tier formulary who continue to use Boniva after October 31, 2008 will be responsible for paying 100 percent of the retail cost of the medication.
- For members on a 2 or 3-tier prescription drug benefit, generally Production Hourly participants, requests for **Boniva** will require prior trials of both Step A and Step B as well as a prior authorization.

Prior authorization forms can be found by logging on to CatHealthBenefits.com, clicking on "For Providers" at the top of the screen, clicking on "Prescription Drugs" on the left-hand side of the screen and clicking on "Prior Authorization List/Forms" on the left-hand side of the screen.

These evidence-based plan changes support Caterpillar's ongoing efforts to encourage members to use the most cost-effective therapies that are appropriate for them. We recognize the additional work this creates for you and appreciate your cooperation in helping your patients get the greatest value from their prescription drugs. We welcome your questions and comments.

If you conclude that receipt of a list of your patients who filled a prescription for either Actonel or Boniva within the past six months is necessary for their care, you may request such a list by contacting RESTAT at 877-228-7909.

Sincerely,

Rick Luetkemeyer, M.D.
Caterpillar Inc.
Corporate Medical
309-675-4687

Rick Horndasch, M.D.
Caterpillar Inc.
Corporate Medical
309-494-0053

Caterpillar's prescription drug benefits are provided pursuant to written plan documents in compliance with the Employee Retirement Income Security Act of 1974, as amended. In the event of any inconsistency between the information in this letter and the plan documents, the plan documents shall govern. As permitted by applicable law, Caterpillar has reserved the right to amend, modify or terminate its prescription drug benefit plans at any time.